Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
ad [2018/11/18 10:50] sflitman [Alzheimer's Disease and Mild Cognitive Impairment] |
ad [2019/07/21 11:46] (current) sflitman [Alzheimer's Disease and Mild Cognitive Impairment] |
||
|---|---|---|---|
| Line 4: | Line 4: | ||
| ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ | ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ | ||
| - | | MCI and Mild AD | Intravenous anti-tau antibody | III | Yes | 33% | 18 months | 5 years | | + | | Mild to Moderate AD | Antibiotic vs. P. gingivalis | II | Yes | 33% | 12 months | None | |
| - | | MCI and Mild AD | Oral BACE inhibitor | III | Yes | 50% | 48 weeks | 1+ years | | + | | Mild to Moderate AD | Oral neuroprotectant | II | Yes | 33% | 12 months | none | |
| | MCI and Mild AD | Counterpulsation device | III | Yes | 50% | 24 weeks | 1 year | | | MCI and Mild AD | Counterpulsation device | III | Yes | 50% | 24 weeks | 1 year | | ||
| - | | Agitation in AD | Oral 5HT2A antagonist | III | Yes | 50% | 8 weeks | None | | ||
| | Agitation in AD | Oral combination of two approved drugs | III | Yes | 33% | 5 weeks | None | | | Agitation in AD | Oral combination of two approved drugs | III | Yes | 33% | 5 weeks | None | | ||
